Cetuximab, a mouse-human chimeric antibody that binds to the extracellular domain of EGFR and blocks ligand-induced activation of EGFR [1], has been approved by the US Food and Drug Administration (FDA) for treatment of metastatic colorectal cancer and metastatic head and neck cancer. The gene discussed is EGFR; the disease is metastatic colorectal cancer.